Posts

Posted on

UVJC Launches NovaJet, First Commercial System Built on Universal Vapor Jet Printing Platform

UVJC Launches NovaJet, First Commercial System Built on Universal Vapor Jet Printing Platform

  • Customer-ready, NovaJet brings dry, solvent-free patterned deposition to advanced materials and next-generation manufacturing.
  • Designed to help customers move from materials discovery and process validation toward manufacturing deployment.

SINGAPORE–(BUSINESS WIRE)–Universal Vapor Jet Corporation (UVJC), a wholly-owned subsidiary of Universal Display Corporation (UDC) (Nasdaq: OLED), today announced the official launch of NovaJet, the first commercial system built on its proprietary Universal Vapor Jet Printing (UVJP) platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013909532/en/

NovaJet, first commercial Universal Vapor Jet Printing platform

NovaJet, first commercial Universal Vapor Jet Printing platform

Available to order now and ready for deployment at customer sites, NovaJet provides materials scientists, process engineers and manufacturers with a customer-ready platform to evaluate advanced materials, develop deposition processes and validate applications across a range of industries. The system deposits functional materials directly onto substrates including silicon wafers, glass, polymers and metals, supporting the development of next-generation technologies across semiconductor, electronics and other advanced manufacturing applications. Developed and built in Singapore, the system advances the commercialization of UVJP technology and expands UVJC’s ability to support customers from application development through manufacturing implementation.

“NovaJet is the first commercial realization of our Universal Vapor Jet Printing platform,” said Chandran Nair, Chief Executive Officer of UVJC. “As industries pursue increasingly advanced materials and device architectures, bridging the gap between innovation and manufacturing has become essential. NovaJet was designed to give researchers, engineers and manufacturers a highly flexible platform for advancing new materials, developing processes and accelerating the path toward commercial production.”

NovaJet is being showcased to customers, researchers and industry partners at the WESEMiBAY Semiconductor Ecosystem Conference and Expo in Shenzhen, China. Visitors to UVJC’s Booth 8G03 can view coated substrates and printed samples produced on the company’s production system in Singapore, alongside a scale model of the NovaJet platform.

From Laboratory Validation to Manufacturing

The discovery of a promising new material is only the first step toward commercial adoption. Bringing advanced materials from laboratory research into scalable manufacturing often requires extensive process development, application qualification and production optimization. NovaJet is designed to help address this challenge by providing a flexible environment where materials scientists, process engineers and manufacturers can validate advanced materials, deposition processes and applications in laboratory settings before progressing toward larger-scale production.

Built on UVJC’s proprietary UVJP technology, NovaJet enables precise, solvent-free deposition of functional materials without the use of solvents, masks or conventional lithography. By bringing multiple stages of thin-film development onto a single dry platform, NovaJet helps streamline workflows while providing greater flexibility for process exploration and optimization.

Once a process has been validated on NovaJet, UVJC can work with customers to support its transition into production through UVJP process and application intellectual property tailored to specific production requirements and end-use applications. Depending on customer needs, this may include larger-scale, automated or customised UVJP systems, including integrated, roll-to-roll and large-area production systems, over time.

Applications Across Advanced Industries

NovaJet is suited for applications where precise, solvent-free and digitally patterned deposition can offer meaningful advantages in materials development and advanced manufacturing. These include semiconductor advanced packaging, perovskites and solar technologies, biomedical and pharmaceutical applications, surface-energy modification, and sensors and monitoring systems.

The platform operates without substrate heating, making it suitable for delicate, non-planar and temperature-sensitive surfaces. It can also support multiple materials and graded compositions within a single process step, enabling the exploration of complex material systems and device architectures across a broad range of industries. By providing a pathway from early-stage research through process qualification and manufacturing scale-up, NovaJet is designed to help accelerate the translation of advanced materials innovation into commercial technologies.

Following its debut at WESEMiBAY, UVJC plans to showcase NovaJet at industry and technical events worldwide, including the 2026 MRS Fall Meeting & Exhibit in Boston, Massachusetts, which runs from 1 to 4 December.

To learn more about NovaJet, discuss evaluation opportunities or schedule a consultation, contact [email protected].

About Universal Vapor Jet Corporation

Universal Vapor Jet Corporation (UVJC), a wholly-owned subsidiary of Universal Display Corporation (UDC), is at the forefront of developing cutting-edge tools and processes that bridge the gap between laboratory research and industrial-scale applications.

Leveraging its proprietary Universal Vapor Jet Printing (UVJP) technology, UVJC offers scalable, solvent-free, and maskless thin-film print and deposition solutions across a spectrum of industries, including semiconductors, electronics, life sciences and renewable energy. The innovative technology is designed to meet the growing demands of precision manufacturing while offering greater efficiency and sustainability. Established in 2024, UVJC is headquartered in Singapore.

To learn more about Universal Vapor Jet Corporation, please visit www.uvjc.com.

(OLED-C)

Media contacts


UVJC Communications

[email protected]

KEYWORDS: Massachusetts China United States Singapore Southeast Asia North America Asia Pacific

INDUSTRY KEYWORDS: Hardware Chemicals/Plastics Semiconductor Alternative Energy Energy Manufacturing Technology Nanotechnology Science Biotechnology Packaging Other Science Health Engineering Research

MEDIA:

Photo
Photo
NovaJet, first commercial Universal Vapor Jet Printing platform
Logo
Logo
Posted on

UVJC Launches NovaJet, First Commercial System Built on Universal Vapor Jet Printing Platform

UVJC Launches NovaJet, First Commercial System Built on Universal Vapor Jet Printing Platform

  • Customer-ready, NovaJet brings dry, solvent-free patterned deposition to advanced materials and next-generation manufacturing.
  • Designed to help customers move from materials discovery and process validation toward manufacturing deployment.

SINGAPORE–(BUSINESS WIRE)–Universal Vapor Jet Corporation (UVJC), a wholly-owned subsidiary of Universal Display Corporation (UDC) (Nasdaq: OLED), today announced the official launch of NovaJet, the first commercial system built on its proprietary Universal Vapor Jet Printing (UVJP) platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013887952/en/

NovaJet, first commercial Universal Vapor Jet Printing platform

NovaJet, first commercial Universal Vapor Jet Printing platform

Available to order now and ready for deployment at customer sites, NovaJet provides materials scientists, process engineers and manufacturers with a customer-ready platform to evaluate advanced materials, develop deposition processes and validate applications across a range of industries. The system deposits functional materials directly onto substrates including silicon wafers, glass, polymers and metals, supporting the development of next-generation technologies across semiconductor, electronics and other advanced manufacturing applications. Developed and built in Singapore, the system advances the commercialization of UVJP technology and expands UVJC’s ability to support customers from application development through manufacturing implementation.

“NovaJet is the first commercial realization of our Universal Vapor Jet Printing platform,” said Chandran Nair, Chief Executive Officer of UVJC. “As industries pursue increasingly advanced materials and device architectures, bridging the gap between innovation and manufacturing has become essential. NovaJet was designed to give researchers, engineers and manufacturers a highly flexible platform for advancing new materials, developing processes and accelerating the path toward commercial production.”

NovaJet is being showcased to customers, researchers and industry partners at the WESEMiBAY Semiconductor Ecosystem Conference and Expo in Shenzhen, China. Visitors to UVJC’s Booth 8G03 can view coated substrates and printed samples produced on the company’s production system in Singapore, alongside a scale model of the NovaJet platform.

From Laboratory Validation to Manufacturing

The discovery of a promising new material is only the first step toward commercial adoption. Bringing advanced materials from laboratory research into scalable manufacturing often requires extensive process development, application qualification and production optimization. NovaJet is designed to help address this challenge by providing a flexible environment where materials scientists, process engineers and manufacturers can validate advanced materials, deposition processes and applications in laboratory settings before progressing toward larger-scale production.

Built on UVJC’s proprietary UVJP technology, NovaJet enables precise, solvent-free deposition of functional materials without the use of solvents, masks or conventional lithography. By bringing multiple stages of thin-film development onto a single dry platform, NovaJet helps streamline workflows while providing greater flexibility for process exploration and optimization.

Once a process has been validated on NovaJet, UVJC can work with customers to support its transition into production through UVJP process and application intellectual property tailored to specific production requirements and end-use applications. Depending on customer needs, this may include larger-scale, automated or customised UVJP systems, including integrated, roll-to-roll and large-area production systems, over time.

Applications Across Advanced Industries

NovaJet is suited for applications where precise, solvent-free and digitally patterned deposition can offer meaningful advantages in materials development and advanced manufacturing. These include semiconductor advanced packaging, perovskites and solar technologies, biomedical and pharmaceutical applications, surface-energy modification, and sensors and monitoring systems.

The platform operates without substrate heating, making it suitable for delicate, non-planar and temperature-sensitive surfaces. It can also support multiple materials and graded compositions within a single process step, enabling the exploration of complex material systems and device architectures across a broad range of industries. By providing a pathway from early-stage research through process qualification and manufacturing scale-up, NovaJet is designed to help accelerate the translation of advanced materials innovation into commercial technologies.

Following its debut at WESEMiBAY, UVJC plans to showcase NovaJet at industry and technical events worldwide, including the 2026 MRS Fall Meeting & Exhibit in Boston, Massachusetts, which runs from 1 to 4 December.

To learn more about NovaJet, discuss evaluation opportunities or schedule a consultation, contact [email protected].

About Universal Vapor Jet Corporation

Universal Vapor Jet Corporation (UVJC), a wholly-owned subsidiary of Universal Display Corporation (UDC), is at the forefront of developing cutting-edge tools and processes that bridge the gap between laboratory research and industrial-scale applications.

Leveraging its proprietary Universal Vapor Jet Printing (UVJP) technology, UVJC offers scalable, solvent-free, and maskless thin-film print and deposition solutions across a spectrum of industries, including semiconductors, electronics, life sciences and renewable energy. The innovative technology is designed to meet the growing demands of precision manufacturing while offering greater efficiency and sustainability. Established in 2024, UVJC is headquartered in Singapore.

To learn more about Universal Vapor Jet Corporation, please visit www.uvjc.com.

Media contacts

UVJC Communications

[email protected]

KEYWORDS: Massachusetts China United States Singapore Southeast Asia North America Asia Pacific

INDUSTRY KEYWORDS: Chemicals/Plastics Semiconductor Alternative Energy Energy Manufacturing Technology Nanotechnology Other Manufacturing Science Biotechnology Packaging Other Science Health Engineering Research

MEDIA:

Photo
Photo
NovaJet, first commercial Universal Vapor Jet Printing platform
Logo
Logo
Posted on

Asia Pacific AI Demand Drives Record Growth, Spending on Tech Services in Q3, ISG Index™ Shows

Asia Pacific AI Demand Drives Record Growth, Spending on Tech Services in Q3, ISG Index™ Shows

Combined market up 80%, as XaaS soars 92% and managed services climbs 16%

SYDNEY–(BUSINESS WIRE)–
Unprecedented demand for AI drove record growth and spending on technology services in Asia Pacific during the third quarter, the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, finds.

The Asia Pacific ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows third-quarter ACV for the combined market (both traditional managed services and cloud-based infrastructure and software services) shot up 80 percent—the region’s highest growth rate ever—to a record US $10.0 billion—the first time ever spending has reached the $10 billion mark in a quarter.

“AI is rocket fuel for the Asia Pacific market,” said Michael Gale, partner and regional leader, ISG Asia Pacific. “We are seeing unprecedented demand for cloud infrastructure to support AI computing needs, as well as for software services, which are fast becoming the key means by which employees are using AI. Traditional managed services also is seeing strong growth as a lever to lower costs and free up funds for AI investment.”

The ISG Index shows spending on cloud-based services (as-a-service, or XaaS) soared 92 percent year on year, its highest growth rate since 2018, to a record US $9.0 billion. Within the XaaS segment, infrastructure-as-a-service (IaaS) ACV essentially doubled (up 99 percent), to a record US $8.3 billion, while software-as-a-service (SaaS) ACV jumped 37 percent, to US $681 million.

Traditional managed services rose 16 percent, to just over US $1.0 billion, the second quarter in a row managed services ACV topped the US $1 billion mark. Within this segment, IT outsourcing (ITO) ACV climbed 41 percent, to US $785 million, with spending across most areas up sharply, offsetting a decline in application development and maintenance (ADM) services. Business process outsourcing (BPO), meanwhile, skyrocketed by 281 percent, to US $209 million, driven by 5X growth in industry-specific services. Engineering, research and development (ER&D) services, on the other hand, fell by 82 percent, to US $52 million, as AI impacted demand for software engineering services.

During the quarter, 55 managed services contracts were awarded, down 8 percent year on year, as small discretionary deal volume faltered.

Among industries, ACV in the banking, financial services and insurance (BFSI) sector was up triple digits (107 percent), while manufacturing rose 11 percent, breaking a streak of five straight quarters of declining results. With a 53 percent drop in ACV, the telecommunications sector, however, remained in the doldrums, down for the third straight quarter.

Geographically, the region’s smaller markets were the source of growth, with Southeast Asia up 16 percent and Korean up 10 times the prior year. The region’s largest market—Australia and New Zealand—was flat year on year, while India declined 10 percent.

Nine-Month Results

Asia Pacific’s combined market ACV rose 50 percent year to date, to US $25.0 billion.

The XaaS segment climbed 56 percent, to US $22.1 billion, accounting for 89 percent of the combined market. Within XaaS, IaaS climbed 61 percent, to US $20.3 billion, while SaaS rose 18 percent, to US $1.8 billion.

Managed services rose 12 percent, to US $2.9 billion. ITO was up 17 percent, to US $2.0 billion, and BPO advanced 37 percent, to US $470 million, while ER&D fell 21 percent, to US $387 million. The 170 managed services contracts awarded year to date were down 9 percent from the prior year.

2026 Global Forecast

For the full year, ISG is maintaining its forecast of 2.1 percent growth for managed services. At the same time, ISG is raising its previous growth forecast for cloud-based XaaS to 60 percent, up from 30 percent last quarter. Within this segment, IaaS is expected to grow 80 percent and SaaS is expected to grow 12.5 percent—the first time ISG has broken out IaaS and SaaS in its public forecasts.

About the ISG Index™

The ISG Index™ is recognized as the authoritative source for marketplace intelligence on the global technology and business services industry. For 96 consecutive quarters, it has detailed the latest industry data and trends for financial analysts, enterprise buyers, software and service providers, law firms, universities and the media.

The 3Q26 Global ISG Index results were presented during a webcast on October 8. To view a replay of the webcast and download the presentation slides, visit this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Will Thoretz, ISG

+1 203 517 3119

[email protected]

Erik Arvidson, Matter Communications for ISG

+1 978 518 4542

[email protected]

KEYWORDS: Connecticut North America United States Asia Pacific Australia Australia/Oceania

INDUSTRY KEYWORDS: Software Data Analytics Internet Consulting Artificial Intelligence Data Management Professional Services Technology

MEDIA:

Logo
Logo
Posted on

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

 — Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan’s National Health Insurance drug price list —

— IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity —

BOSTON, Oct. 13, 2026 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the commercial launch of IMCIVREE® (setmelanotide) in Japan to treat patients living with acquired hypothalamic obesity (HO), following its inclusion on Japan’s National Health Insurance (NHI) drug price list. IMCIVREE is the first approved therapy in Japan for acquired HO.

“This launch marks an important advancement for people living with acquired HO in Japan where there were no approved therapies for this disease until now,” said Yann Mazabraud, Executive Vice President and Head of International at Rhythm. “We have been building our team in Japan in preparation for this launch and are excited about the opportunity to positively impact the lives of Japanese patients. This is a significant milestone in our global efforts to bring innovative therapies to patients with rare neuroendocrine diseases around the world.”

The launch follows approval by Japan’s Ministry of Health, Labour and Welfare (MHLW) of IMCIVREE for acquired hypothalamic obesity in August of this year. The approval was supported by data from the pivotal Phase 3 TRANSCEND trial, which enrolled 142 patients with acquired HO, including 12 patients from a Japanese cohort and 10 supplemental patients enrolled in addition to the primary 120-patient pivotal cohort. The global study met its primary endpoint, demonstrating a statistically significant 18.8% placebo-adjusted reduction in body mass index (BMI).

As previously announced, setmelanotide received orphan drug designation from the MHLW for the treatment of acquired hypothalamic obesity. Rhythm estimates that approximately 5,000 to 8,000 people are living with acquired HO in Japan.

About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity, adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and control of hunger in patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment; and for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.

Setmelanotide Indication
In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity, in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above, and for the treatment of obesity and control of hunger in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician experienced in the diagnosis and management of rare forms of obesity with genetic or hypothalamic origin.

Limitations of Use
Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:

  • Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign
  • Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity.

Important Safety Information

CONTRAINDICATIONS

Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.

WARNINGS AND PRECAUTIONS

Disturbance in Sexual Arousal: Spontaneous penile erections and increased frequency of penile erections in males have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

Depression and Suicidal Ideation: Depression and suicidal ideation have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.

Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.

Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: Generalized or focal increases in skin pigmentation occurred in the majority of IMCIVREE-treated patients. IMCIVREE may also cause development of new melanocytic nevi or darkening of pre-existing nevi. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.

Acute Adrenal Insufficiency with Acquired HO: Patients with acquired HO and secondary adrenal insufficiency reported serious adverse reactions related to acute adrenal insufficiency in 5% of IMCIVREE-treated patients and no placebo-treated patients. In patients with secondary adrenal insufficiency, monitor for clinical signs of acute adrenal insufficiency.

Sodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus: Patients with acquired HO and concomitant central diabetes insipidus (DI)/arginine vasopressin (AVP) deficiency reported hyponatremia in 6% of IMCIVREE-treated patients and 2% of placebo-treated patients and hypernatremia in 5% of IMCIVREE-treated patients and 4% of placebo-treated patients. Monitor serum sodium levels with changes in fluid intake and hydration status. Adjust the doses of concomitant therapies for DI/AVP deficiency as needed.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥20% in at least 1 indication) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.

USE IN SPECIFIC POPULATIONS

Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.

Please see the full Prescribing Information for additional Important Safety Information.

Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the safety, efficacy, potential benefits of, and clinical design or progress of any of our products or product candidates at any dosage or in any indication, including, setmelanotide, bivamelagon, and RM-718; the use of setmelanotide in patients with acquired HO and the success of our commercialization of IMCIVREE for acquired HO; our expectations surrounding potential regulatory submissions, progress, or approvals and timing thereof for any of our product candidates, including launch in Japan; the estimated market size and addressable population for our drug products, including setmelanotide for the treatment of acquired HO; and the timing of any of the foregoing. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international operations and the costs of any related compliance programs, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors, including those discussed under the caption “Risk Factors” in Rhythm’s Quarterly Report on Form 10-Q for the three months ended June 30, 2026, and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Corporate Contacts:

David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
[email protected]  

Kate Walsh
Director, Corporate Communications
Rhythm Pharmaceuticals, Inc.
(857) 264-4280
[email protected]



Posted on

Rithm Property Trust Schedules Third Quarter 2026 Earnings Release

Rithm Property Trust Schedules Third Quarter 2026 Earnings Release

NEW YORK–(BUSINESS WIRE)–
Rithm Property Trust Inc. (NYSE: RPT, “Rithm Property Trust” or the “Company”), an opportunistic commercial real estate investment vehicle externally managed by an affiliate of Rithm Capital Corp., announced today that it will release its third quarter 2026 financial results for the period ended September 30, 2026, on Wednesday, October 21, 2026, after the close of trading on the New York Stock Exchange.

The press release will be available in the Quarterly Results section of Rithm Property Trust’s website: https://www.rithmpropertytrust.com/financials/quarterly-results/default.aspx.

Rithm Property Trust will not host a conference call to discuss these results. The investor relations team remains available for questions at [email protected].

About Rithm Property Trust Inc.

Rithm Property Trust is an opportunistic commercial real estate investment vehicle externally managed by an affiliate of Rithm Capital Corp. (NYSE: RITM). Rithm Property Trust is a Maryland corporation that is organized and conducts its operations to qualify as a real estate investment trust (REIT) for federal income tax purposes.

Investor Relations

(646) 868-5483

[email protected]

Media

Jonathan Gasthalter/Sam Cohen

Gasthalter & Co.

212-257-4170

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: REIT Finance Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Logo
Logo
Posted on

Globavend Holdings to Present at the 2026 ThinkEquity Conference

Presentation to highlight established logistics operations and growth strategy spanning AI-powered digital entertainment and live events

PERTH, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) — via IBN — Globavend Holdings Limited (NASDAQ: GVH) (“Globavend” or the “Company”), an emerging e-commerce logistics provider and AI-powered digital entertainment company, today announced that its Chairman, Kenny K.M. Fung, will present at the 2026 ThinkEquity Conference on Thursday, October 15, 2026, at the Mandarin Oriental Hotel in New York City.

Mr. Fung will provide an overview of Globavend’s business, recent developments and growth strategy, highlighting the Company’s established cross-border logistics operations alongside its expansion into digital and live entertainment through Loomi Entertainment Group Limited.

The presentation will discuss Globavend’s established cross-border logistics business and the growth opportunities in Australia and New Zealand’s e-commerce markets, alongside its entertainment business model combining AI-assisted content production, original intellectual property and international distribution. Topics will include Imaginary, the Company’s proprietary AI-powered cinematic production platform; its Loomi: Short Drama streaming application; distribution through third-party platforms such as DramaBox; and the development of its live entertainment activities.

“Our logistics business remains the foundation of Globavend as we develop additional growth opportunities in entertainment,” said Kai Man Fung, Chairman of Globavend. “We look forward to sharing how our proprietary production technology, original content and distribution capabilities support our entertainment strategy, and how these initiatives complement our established logistics operations. ThinkEquity provides an opportunity to explain our progress and long-term direction to the investment community.”

Presentation Details

  • Conference: 2026 ThinkEquity Conference
  • Date: Thursday, October 15, 2026
  • Presentation Time: 3:30 p.m. Eastern Time
  • Presenter: Kenny K.M. Fung, Chairman, Globavend Holdings Limited
  • Location: Mandarin Oriental Hotel, 80 Columbus Circle, New York, NY
  • Live Webcast:
    https://bit.ly/4jPUxeC

Investors, analysts and other interested parties are invited to watch the presentation through the live webcast.

Additional conference information is available at https://www.think-equity.com/thinkequity-conference.

About Globavend Holdings Limited

Globavend Holdings Limited (NASDAQ: GVH) is an emerging e-commerce logistics provider and AI-powered digital entertainment company. As a logistics provider, the Company offers integrated cross-border logistics solutions across Hong Kong, Australia, New Zealand and mainland China. As a digital entertainment company, the Company develops generative AI-assisted cinematic production workflows, multimodal content generation capabilities and multilingual digital entertainment distribution solutions through its proprietary AI technologies. It operates Loomi: Short Drama, a mobile streaming platform offering professionally produced multilingual micro dramas, and Imaginary, its proprietary AI-powered cinematic production platform, providing end-to-end AI-assisted content creation capabilities. By combining AI-powered production technologies with proprietary distribution capabilities, Globavend is building an integrated digital entertainment ecosystem while continuing to expand its established cross-border logistics business.

Forward-Looking Statements

This press release contains forward-looking statements concerning the Company’s anticipated conference participation, business strategy, entertainment initiatives and growth opportunities. These statements reflect management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks relating to strategy execution, content commercialization, competition, financing and market conditions. Further information regarding these and other risks is included in the Company’s Annual Report on Form 20-F for the year ended September 30, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by law.

For Investor and Media Inquiries

Globavend Holdings Limited
Kenny K. M. Fung, Chairman
[email protected]
888.201.1623
https://globavend.com/



Posted on

MPT Named to Modern Healthcare’s Best Places to Work 2026 and Newsweek’s America’s Greenest Companies 2027

MPT Named to Modern Healthcare’s Best Places to Work 2026 and Newsweek’s America’s Greenest Companies 2027

Achieves Top 10 Ranking Among Healthcare Suppliers from Modern Healthcare

BIRMINGHAM, Ala.–(BUSINESS WIRE)–
Medical Properties Trust, Inc. (the “Company” or “MPT”) (NYSE: MPT) today announced that, for the sixth consecutive year, it was named one of Modern Healthcare’s Best Places to Work in healthcare and, for the second time, one of America’s Greenest Companies by Newsweek and Plant-A Insights Group.

“Continuing to be recognized by Modern Healthcare and Newsweek is a tremendous honor,” said Edward K. Aldag, Jr., MPT’s Chairman, President, and CEO. “While these recognitions highlight different areas of our business, both reflect our commitment to being a responsible company, whether through the workplace we create for our employees or the environmental practices we advance across our footprint. We are proud of the continued progress these recognitions represent and are grateful to our employees who make that progress possible.”

The annual Best Places to Work in Healthcare program identifies and honors outstanding employers throughout the healthcare industry nationwide. Modern Healthcare partners with Workforce Research Group to conduct a rigorous assessment process, which includes an extensive employee survey.

Newsweek’s America’s Greenest Companies recognition is based on an evaluation of environmental performance indicators, including greenhouse gas emissions, water usage, waste generation, sustainability disclosures and environmental commitments, highlighting organizations that are making measurable progress in reducing their environmental impact and advancing sustainability initiatives.

About Medical Properties Trust, Inc.

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world’s largest owners of hospital real estate with 373 facilities and approximately 38,000 licensed beds in nine countries and across three continents as of June 30, 2026. MPT’s financing model facilitates acquisitions and recapitalizations, and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations. For more information, please visit the Company’s website at www.mpt.com.

Charles Lambert

Senior Vice President of Finance & Treasurer

Medical Properties Trust, Inc.

(205) 397-8897

[email protected]

KEYWORDS: Alabama United States North America

INDUSTRY KEYWORDS: Health Other Construction & Property Hospitals Commercial Building & Real Estate Construction & Property General Health Building Systems

MEDIA:

Logo
Logo
Posted on

HII is Awarded Contract to Support AUKUS Engineering and Design Work

NEWPORT NEWS, Va., Oct. 13, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that its Newport News Shipbuilding (NNS) division was awarded a $56 million contract by the U.S. Navy for shipbuilding engineering and design in support of the trilateral Australia, United Kingdom, and United States (AUKUS) partnership. The contract includes an option which, if exercised, would bring the cumulative value of this contract to $91 million. HII continues to take a whole-company approach to support the AUKUS agreement, providing services and support for AUKUS across its business divisions.

Under the contract, in support of Foreign Military Sales (FMS) requirements, NNS will continue supporting the United Kingdom and Australia, including technology insertion, engineering, supply chain and workforce development support, and digital transformation. The award also includes the United States Industry Support (USIS) effort, wherein NNS engineers and designers will support the design of the SSN-AUKUS nuclear-powered submarine to be built by the United Kingdom and Australia.

“Our longstanding nuclear experience at NNS directly benefits the AUKUS mission to support shared security objectives,” said Bryan Caccavale, NNS vice president of program management. “We are honored to leverage that experience and contribute even more to the AUKUS partnership.”

An image accompanying this release is available at: http://hii.com/news/hii-is-awarded-contract-to-support-aukus-engineering-and-design-work/. 

The contract award is the latest in a range of initiatives HII is actively engaged in to advance the AUKUS partnership. HII’s Mission Technologies division in Australia was awarded the contract to deliver the Australian Submarine Supplier Qualification (AUSSQ) Program, which accelerates the identification, development and qualification of Australian suppliers for integration into the United States submarine industrial base.

HII is also working with Australian industry and academia in Australia to develop the skilled workforce needed to support Australia’s nuclear-powered submarine enterprise. This includes educating and training thousands of engineers, maritime specialists, nuclear tradespeople and other professionals to support the enterprise across its full lifecycle.

The company was also awarded the Australian Submarine Agency’s Nuclear Capability Advisory Services (ANCAS) contract in December 2025 to support development of Australia’s Nuclear Power Submarine (NPS) programs through nuclear program management and technical support services.  

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 45,000 strong. For more information, visit:

Contact:

Todd Corillo
[email protected]
(757) 688-3220

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/727949c3-e7fb-47d8-a061-7e346f238365



Posted on

Five Star Bancorp Announces Third Quarter 2026 Earnings Release Date and Webcast

RANCHO CORDOVA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) — Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank (the “Bank”), expects to report its financial results for the quarter ended September 30, 2026, after the stock market closes on Monday, October 26, 2026.

Management will host a live webcast for analysts and investors to review this information at 1:00 PM ET (10:00 AM PT) on October 27, 2026.

The live webcast will be accessible from the “News & Events” section of the Company’s website under “Events” at https://investors.fivestarbank.com/news-events/events. Please pre-register for the event using this link. The webcast will be archived on the Company’s website for a period of 90 days.

About Five Star Bancorp

Five Star is a bank holding company headquartered in Rancho Cordova, California. Five Star operates through its wholly owned banking subsidiary, Five Star Bank. The Bank has ten branches in California. For more information, visit https://www.fivestarbank.com.

Investor Contact:

Heather C. Luck, Chief Financial Officer
Five Star Bancorp
(916) 626-5008
[email protected]

Media Contact:

Shelley R. Wetton, Chief Marketing Officer
Five Star Bancorp
(916) 284-7827
[email protected]



Posted on

Distribution Solutions Group Announces Strategic Acquisition of Winzer and FastServ Supply

Distribution Solutions Group Announces Strategic Acquisition of Winzer and FastServ Supply

Expands MRO Distribution Network through Enhanced Customer Reach and Geographic Coverage

FORT WORTH, Texas–(BUSINESS WIRE)–Distribution Solutions Group, Inc. (NASDAQ: DSGR) (“DSG” or the “Company”), a premier specialty distribution company, today announced a definitive agreement to acquire GradeEight Holdings, LLC (“GradeEight”), a multi-brand MRO distribution platform utilizing a national network of franchisees under Winzer Corporation (“Winzer”), and retail-facing storefronts through FastServ Supply located in Texas and Arkansas.

Founded in 1978, Winzer is a principal operating company of GradeEight Holdings, LLC. Through its MRO distribution model, Winzer serves customers across all 50 states, Puerto Rico, Mexico, and Canada, supported by distribution facilities in Texas and Michigan. A key differentiator of the business is its network of more than 270 franchisees, serving approximately 12,000 customers and providing access to a product portfolio of over 65,000 SKUs. In addition to its MRO distribution operations, GradeEight operates FastServ Supply, a brick-and-mortar retail chain with eight locations across Texas and Arkansas. Both businesses, along with their e-commerce site, serve a diverse range of end markets, including automotive, construction, manufacturing, transportation & logistics, government and public sector, energy, agriculture, and other industrial sectors.

“GradeEight, through its Winzer and FastServ Supply businesses, has successfully built a differentiated on-site business with committed franchisees serving a loyal customer base and enjoying a strong market presence across the MRO market and retail channels,” said J. Bryan King, Chairman and Chief Executive Officer of Distribution Solutions Group. “Their complementary capabilities, broad marketplace coverage, and established presence enhance DSG’s platform and our ability to serve customers across key regions. We are excited to invest in tools, products, and other growth opportunities for its franchisees and FastServ locations to deepen engagement with their customers. We are pleased to welcome the GradeEight team to DSG and look forward to leveraging our combined strengths to drive continued growth and value for our customers, suppliers and associates.”

“This transaction represents an exciting new chapter for GradeEight. By joining DSG and working alongside the Lawson Products team, we gain access to expanded resources, product categories, and operational capabilities that will benefit our customers and supplier partners,” said Cody Patterson, CEO of GradeEight Holdings. “We are grateful for the relationships we have developed over the years and believe this combination positions our franchisees, our business and our employees for continued success and new opportunities in the future.”

GradeEight Holdings generates approximately $110 million in annual sales and is expected to be accretive to DSG’s Adjusted EBITDA margins on a go-forward basis. The transaction will be funded through DSG’s existing cash and availability under its amended credit agreement and is expected to close in the fourth quarter of 2026, subject to customary closing conditions.

About GradeEight Holdings

GradeEight Holdings is a national distributor of Maintenance, Repair, and Operations (MRO) products with approximately 190 associates and 270 franchisees serving customers across the United States. GradeEight supplies fasteners, electrical supplies, chemicals, shop supplies, automotive supplies, safety supplies, cutting tools, abrasives, hydraulics, and janitorial supplies. GradeEight’s mission is to build a great MRO company by providing quality products and comprehensive solutions through unmatched service while helping customers succeed and associates thrive.

About Distribution Solutions Group, Inc.

DSG is a premier multi-platform specialty distribution company providing high-touch, value-added distribution solutions to the maintenance, repair & operations (MRO), original equipment manufacturer (OEM) and industrial technologies markets. DSG was formed through the strategic combination of Lawson Products, a leader in MRO distribution of C-parts, including the Canada Branch Division; Gexpro Services, a leading global supply chain services provider to manufacturing customers; and TestEquity, a leader in electronic test & measurement and supply solutions.

Through its collective businesses, DSG is dedicated to helping customers lower their total cost of operation by increasing productivity and efficiency with the right products, expert technical support, and fast, reliable delivery to be a one-stop solution provider. DSG serves over 200,000 customers in several diverse end markets supported by approximately 4,300 dedicated employees and strong vendor partnerships. DSG ships from strategically located distribution and service centers to customers in North America, Europe, Asia, South America and the Middle East.

For more information on Distribution Solutions Group, please visit www.distributionsolutionsgroup.com.

Forward-Looking Statements

This release contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the “safe-harbor” provisions under the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. The Terms “aim,” “anticipate,” “believe,” “contemplates,” “continues,” “could,” “ensure,” “estimate,” “expect,” “forecasts,” “if,” “intend,” “likely,” “may,” “might,” “objective,” “outlook,” “plan,” “positioned,” “potential,” “predict,” “probable,” “project,” “shall,” “should,” “strategy,” “will,” “would,” and variations of them and other words and terms of similar meaning and expression (and the negatives of such words and terms) are intended to identify forward-looking statements.

Forward-looking statements can also be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations and involve inherent risks, uncertainties and assumptions, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. DSG can give no assurance that any goal or plan set forth in forward-looking statements can be achieved and DSG cautions readers not to place undue reliance on such statements. DSG undertakes no obligation to release publicly any revisions to forward-looking statements as a result of new information, future events or otherwise. Each forward-looking statement speaks only as of the date on which such statement is made, and DSG undertakes no obligation to update any such statement to reflect events or circumstances arising after such date. Actual results may differ materially from those projected as a result of certain risks and uncertainties. Factors that could cause or contribute to such differences or that might otherwise impact DSG’s business, financial condition and results of operations include the risks that DSG may encounter difficulties integrating the business of DSG with the business of other companies that DSG has combined with or may otherwise combine with and that certain assumptions with respect to such business or transactions could prove to be inaccurate. Certain risks associated with DSG’s business are also discussed from time to time in the reports DSG files with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K or other reports the Company may file from time to time with the Securities and Exchange Commission, which should be reviewed carefully.

Company:

Distribution Solutions Group, Inc.

Ronald J. Knutson

Executive Vice President, Chief Financial Officer and Treasurer

1-888-611-9888

Investor Relations:

Three Part Advisors, LLC

Steven Hooser / Sandy Martin

214-872-2710 / 214-616-2207

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Other Manufacturing Construction & Property Trucking Packaging Transport Automotive Manufacturing Building Systems Manufacturing Logistics/Supply Chain Management Other Construction & Property

MEDIA:

Logo
Logo